SALME Fundamental Analysis - SALMON EVOLUTION ASA

Fundamental Rating

SALME gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 59 industry peers in the Food Products industry. SALME has a bad profitability rating. Also its financial health evaluation is rather negative. SALME is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year SALME has reported negative net income.

SALME had a negative operating cash flow in the past year.

In the past 5 years SALME always reported negative net income.

SALME had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

SALME's Return On Assets of -5.15% is on the low side compared to the rest of the industry. SALME is outperformed by 81.36% of its industry peers.

With a Return On Equity value of -8.41%, SALME is not doing good in the industry: 79.66% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-5.15%
ROE	-8.41%
ROIC	N/A

ROA(3y)-2.76%

ROA(5y)-2.34%

ROE(3y)-3.94%

ROE(5y)-3.2%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SALME has a Gross Margin of 62.88%. This is amongst the best in the industry. SALME outperforms 91.53% of its industry peers.

In the last couple of years the Gross Margin of SALME has declined.

The Profit Margin and Operating Margin are not available for SALME so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	62.88%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-11.83%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SALME does not have a ROIC to compare to the WACC, probably because it is not profitable.

SALME has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, SALME has more shares outstanding

The debt/assets ratio for SALME has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 0.89, we must say that SALME is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.89, SALME is doing worse than 81.36% of the companies in the same industry.

A Debt/Equity ratio of 0.41 indicates that SALME is not too dependend on debt financing.

SALME has a better Debt to Equity ratio (0.41) than 67.80% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	N/A
Altman-Z	0.89

ROIC/WACCN/A

WACC7.84%

2.3 Liquidity

A Current Ratio of 0.96 indicates that SALME may have some problems paying its short term obligations.

The Current ratio of SALME (0.96) is worse than 71.19% of its industry peers.

SALME has a Quick Ratio of 0.96. This is a bad value and indicates that SALME is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 0.53, SALME is doing worse than 74.58% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	0.96
Quick Ratio	0.53

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SALME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -152.94%.

The Revenue has grown by 205.07% in the past year. This is a very strong growth!

SALME shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 238.62% yearly.

EPS 1Y (TTM)-152.94%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-66.67%

Revenue 1Y (TTM)205.07%

Revenue growth 3Y238.62%

Revenue growth 5YN/A

Sales Q2Q%68.54%

3.2 Future

SALME is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 81.13% yearly.

The Revenue is expected to grow by 37.55% on average over the next years. This is a very strong growth

EPS Next Y-279.89%

EPS Next 2Y22.34%

EPS Next 3Y57.88%

EPS Next 5Y81.13%

Revenue Next Year-22.83%

Revenue Next 2Y17.82%

Revenue Next 3Y40.68%

Revenue Next 5Y37.55%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SALME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SALME is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

SALME's earnings are expected to grow with 57.88% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y22.34%

EPS Next 3Y57.88%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for SALME!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SALMON EVOLUTION ASA

OSL:SALME (12/11/2025, 4:16:40 PM)

4.965

0 (0%)

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupFood, Beverage & Tobacco

GICS IndustryFood Products

Earnings (Last)11-11 2025-11-11/bmo

Earnings (Next)02-09 2026-02-09/amc

Inst Owners21.03%

Inst Owner ChangeN/A

Ins Owners2.19%

Ins Owner ChangeN/A

Market Cap2.30B

Revenue(TTM)467.74M

Net Income(TTM)-176.66M

Analysts86.25

Price Target7.82 (57.5%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-215.55%

Min EPS beat(2)-220.42%

Max EPS beat(2)-210.68%

EPS beat(4)1

Avg EPS beat(4)-422.53%

Min EPS beat(4)-1265.05%

Max EPS beat(4)6.04%

EPS beat(8)2

Avg EPS beat(8)-223.01%

EPS beat(12)5

Avg EPS beat(12)-150.61%

EPS beat(16)9

Avg EPS beat(16)-104.98%

Revenue beat(2)0

Avg Revenue beat(2)-30.39%

Min Revenue beat(2)-43.93%

Max Revenue beat(2)-16.84%

Revenue beat(4)1

Avg Revenue beat(4)-23.17%

Min Revenue beat(4)-43.93%

Max Revenue beat(4)1.98%

Revenue beat(8)3

Avg Revenue beat(8)-20.9%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-7.2%

PT rev (3m)-9.21%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-32.01%

EPS NY rev (1m)-0.42%

EPS NY rev (3m)-58.07%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-13.95%

Revenue NY rev (1m)-8%

Revenue NY rev (3m)-16%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	6.73
P/FCF	N/A
P/OCF	N/A
P/B	1.09
P/tB	1.14
EV/EBITDA	N/A

EPS(TTM)-0.43

EYN/A

EPS(NY)-0.06

Fwd EYN/A

FCF(TTM)-1.81

FCFYN/A

OCF(TTM)-0.07

OCFYN/A

SpS0.74

BVpS4.54

TBVpS4.36

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-5.15%
ROE	-8.41%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	62.88%
FCFM	N/A

ROA(3y)-2.76%

ROA(5y)-2.34%

ROE(3y)-3.94%

ROE(5y)-3.2%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-11.83%

GM growth 5YN/A

F-Score2

Asset Turnover0.1

Health

		Industry Rank	Sector Rank
Debt/Equity	0.41
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	988.05%
Cap/Sales	235.51%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.96
Quick Ratio	0.53
Altman-Z	0.89

F-Score2

WACC7.84%

ROIC/WACCN/A

Cap/Depr(3y)4495.02%

Cap/Depr(5y)15899.7%

Cap/Sales(3y)642.51%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-152.94%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-66.67%

EPS Next Y-279.89%

EPS Next 2Y22.34%

EPS Next 3Y57.88%

EPS Next 5Y81.13%

Revenue 1Y (TTM)205.07%

Revenue growth 3Y238.62%

Revenue growth 5YN/A

Sales Q2Q%68.54%

Revenue Next Year-22.83%

Revenue Next 2Y17.82%

Revenue Next 3Y40.68%

Revenue Next 5Y37.55%

EBIT growth 1Y-161.03%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-56473.6%

EBIT Next 3Y1328.21%

EBIT Next 5Y477.46%

FCF growth 1Y-44.33%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y76.05%

OCF growth 3YN/A

OCF growth 5YN/A

SALMON EVOLUTION ASA / SALME.OL FAQ

What is the fundamental rating for SALME stock?

ChartMill assigns a fundamental rating of 2 / 10 to SALME.OL.

Can you provide the valuation status for SALMON EVOLUTION ASA?

ChartMill assigns a valuation rating of 1 / 10 to SALMON EVOLUTION ASA (SALME.OL). This can be considered as Overvalued.

Can you provide the profitability details for SALMON EVOLUTION ASA?

SALMON EVOLUTION ASA (SALME.OL) has a profitability rating of 1 / 10.

SALMON EVOLUTION ASA (SALME.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

SALMON EVOLUTION ASA / SALME.OL FAQ

What is the fundamental rating for SALME stock?

Can you provide the valuation status for SALMON EVOLUTION ASA?

Can you provide the profitability details for SALMON EVOLUTION ASA?